Giuseppe Cabibbo MD, PhD
Università degli Studi di Palermo
H-index: 49
Europe-Italy
Top articles of Giuseppe Cabibbo MD, PhD
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab | Margherita Rimini Margarida Montes Elisabeth Amadeo Francesco Vitiello Masatoshi Kudo | 2024/3/21 | |
A systematic review and meta-analysis of diagnostic outcomes of endoscopic ultrasound guided liver biopsy versus percutaneous liver biopsy | Rana Magdi Farida Elshafeey Mohamed Elshebiny Menna Kamel Yasmeen Abuelnaga | 2020/10/30 | |
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma | Targeted Oncology | Silvia Camera Margherita Rimini Federico Rossari Toshifumi Tada Goki Suda | 2024/1/22 |
OC. 05.4: TREATMENT OF HEPATOCELLULAR CARCINOMA ACCORDING TO MULTIPARAMETRIC THERAPEUTIC HIERARCHY APPROACH: PROSPECTIVE VALIDATION STUDY | Digestive and Liver Disease | L Canova M Iavarone E Alimenti B Antonelli AM Ierardi | 2024/4/1 |
Navigating the Landscape of Liver Cancer Management: Study Designs in Clinical Trials and Clinical Practices | Giuseppe Cabibbo Ciro Celsa Lorenza Rimassa Ferran Torres Jordi Rimola | 2024/2/1 | |
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours | Journal of Hepatology | Ciro Celsa Giuseppe Cabibbo Claudia AM Fulgenzi Bernhard Scheiner Antonio D’Alessio | 2024/3/1 |
α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma | International Journal of Cancer | Federico Rossari Toshifumi Tada Goki Suda Shigeo Shimose Masatoshi Kudo | 2024/3/15 |
T. 07.2: LONG-TERM THERAPY WITH INTRAVENOUS HUMAN ALBUMIN INCREASE SURVIVAL IN PATIENTS WITH DECOMPENSATED CIRRHOSIS AND REFRACTORY ASCITES | Digestive and Liver Disease | A Lombardo L Capodicasa D Alaimo F Mercurio A Zimbardo | 2024/4/1 |
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab | Liver International | Ilario Giovanni Rapposelli Toshifumi Tada Shigeo Shimose Valentina Burgio Takashi Kumada | 2021/12 |
Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real … | Ciro Celsa Naoshi Nishida Ashwini Arvind Susanna Varkey Ulahannan Michael Li | 2024/1/20 | |
Long-term therapy with intravenous human albumin increase survival in patients with decompensated cirrhosis and refractory ascites | Digestive and Liver Disease | A Lombardo L Capodicasa D Alaimo F Mercurio A Zimbardo | 2024/2/1 |
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib | Internal and Emergency Medicine | Bernardo Stefanini Francesco Tovoli Franco Trevisani Mariarosaria Marseglia Giovan Giuseppe Di Costanzo | 2024/3/29 |
Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian … | Digestive and Liver Disease | Giuseppe Cabibbo Bruno Daniele Mauro Borzio Andrea Casadei-Gardini Umberto Cillo | 2024/2/1 |
Reply to:" irLI or not irLI: That is the question" | Journal of hepatology | Ciro Celsa Giuseppe Cabibbo David James Pinato | 2024/3/12 |
Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care | Digestive and Liver Disease | Benedetta Stefanini Laura Bucci Valentina Santi Nicola Reggidori Lorenzo Lani | 2024/2/9 |
T. 07.3: CHARACTERISTICS AND OUTCOMES OF IMMUNOTHERAPYRELATED LIVER INJURY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA COMPARED TO PATIENTS WITH ADVANCED SOLID TUMOURS | Digestive and Liver Disease | C Celsa G Cabibbo CAM Fulgenzi B Scheiner A D'Alessio | 2024/4/1 |
Characteristics and management of hepatocellular carcinoma (HCC) in Sicily: first results of the HCC Sicily Multidisciplinary Network | Digestive and Liver Disease | C Celsa G Cabibbo R Ciccia G Di Maria D Pagano | 2024/2/1 |
Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice | Hepatobiliary Surgery and Nutrition | Ciro Celsa Lucia Cerrito Leonardo Stella Roberta Ciccia Giuseppe Cabibbo | 2023/4/4 |
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population | Margherita Rimini Andrea Casadei-Gardini Mara Persano Toshifumi Tada Goki Suda | 2023/2/1 | |
Clinical impact of relative dose intensity of cabozantinib during the first 8 weeks and of subsequent dose reductions in patients with unresectable hepatocellular carcinoma | Digestive and Liver Disease | F Tovoli V Dadduzio S De Lorenzo L Rimassa G Masi | 2023/9/1 |
Co-Authors
